Potentially Pivotal Study to Evaluate Sarizotan for the Treatment of Apneas in Rett Syndrome
Milan, Italy and Morristown, N.J., USA – July 21, 2016 – Newron Pharmaceuticals S.p.A
Zambon today announces the launch in the Netherlands of Xadago® (safinamide) as an add-on to levodopa alone or in combination with other Parkinson’s disease (PD) medications, in
Milan, Italy and Morristown, N.J., USA – June 27, 2016 – Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN), a biopharmaceutical company focused on the development of novel
Milan, Italy and Morristown, N.J., USA – June 16, 2016 – Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN), a biopharmaceutical company focused on the development of novel
May 25, 2016 – Milan, Italy – Newron Pharmaceuticals S.p.A. (“Newron”) [Ticker: SIX: NWRN], a biopharmaceutical company focused on the development of novel therapies for patients
Zambon today announces the availability in the U.K. of Xadago® (safinamide) for the treatment of adult patients with idiopathic Parkinson’s disease (PD) as an add-on therapy to a
Potentially Pivotal STARS (Sarizotan Treatment of Apneas in Rett Syndrome) Trial is First for Rett’s
Milan, Italy and Morristown, N.J., USA – May 17, 2016 – Newron Pharmaceuticals
Zambon today announces the launch in Denmark and Sweden of Xadago® (safinamide) as an add-on to levodopa alone or in combination with other Parkinson’s disease (PD) medications,
Milan, Italy – April 11, 2016 – Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN), a biopharmaceutical company focused on the development of novel therapies for patients with
Evidence of anti-pyschotic efficacy as an add-on to antipsychotics
Milan, Italy – 5 April 2016 – Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN), a biopharmaceutical company
The information on the following pages may be made available in the United States. By clicking on the link below, you agree that you are in the United States.
